NavigAID SLE is a stratification tool, which separates and defines subgroups of Systemic Lupus Erythematosus (SLE) patients to overcome heterogeneity and enable novel approaches for successful drug development.
Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a heterogeneous range of clinical manifestations that affects multiple organs. Worldwide, approximately 5 million patients are affected.
Recent clinical developments in SLE have focused on inhibiting the activation of autoreactive B-cells, thereby reducing autoantibody production, but several challenges for successful SLE drug development still exist.
One solution is to use novel diagnostic markers and assays for precise disease characterization, patient stratification and response prediction. Protagen’s NavigAID SLE does exactly this and could become part of any clinical development program.
This diagnostic magnifying glass informs NavigAID SLE, which can then separate and define SLE subgroups via the simple measurement of patients’ serum biomarkers, to increase the probability of therapeutic success.
NavigAID SLE enables specific differential diagnosis, disease activity assessment, type-I Interferon signature comparison plus a unique disease stratification approach thereby overcoming heterogeneity and enabling new approaches to successful drug development.
Protagen has recently released a whitepaper discussing the application of the new NavigAID SLE array for patient stratification and the successful development of companion diagnostics, as well as the principle benefits offered by the technology.